Strategies for therapeutic targeting of the p53 pathway in cancer.
Wiman
K G
KG
Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, Stockholm SE-171 76, Sweden. Klas.Wiman@ki.se
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001372:Aza Compounds / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000639:trends*; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D009154:Mutation; D010879:Piperazines / Q000494:pharmacology; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014765:Viral Vaccines
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D007093:Imidazoles; D010879:Piperazines; D016159:Tumor Suppressor Protein p53; D014765:Viral Vaccines; C464532:dl1520; C482203:nutlin 1; D051736:Proto-Oncogene Proteins c-mdm2; C451219:2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one